Open AccessDissolution of metastatic thymic carcinoma–associated right atrial thrombus with rivaroxaban
Author(s) -
Curlene Nimblette,
Rajeev Seecheran,
Jessica Kawall,
Valmiki Seecheran,
Sangeeta Persad,
Koomatie Ramsaroop,
Naveen Seecheran
Publication year - 2020
Publication title -
sage open medical case reports
Language(s) - English
Resource type - Journals
ISSN - 2050-313X
DOI - 10.1177/2050313x20927596
Subject(s) - medicine , rivaroxaban , thymic carcinoma , thrombus , venous thromboembolism , dabigatran , cancer , pulmonary embolism , thymoma , cardiology , surgery , thrombosis , atrial fibrillation , warfarin
Thymic carcinoma typically exhibits more clinically aggressive behavior and portends a worse prognosis as compared to thymoma. Venous thromboembolism is a significant cause of morbidity and mortality in oncologic patients. Traditionally, the standard-of-care management of cancer-associated venous thromboembolism has been therapeutic anticoagulation with low molecular weight heparins; however, with the advent of direct oral anticoagulants, there is an ongoing paradigm shift to transition to these novel agents in an attempt to attenuate cancer-associated venous thromboembolism events. We describe an exceedingly rare case of metastatic thymic carcinoma–associated right atrial thrombus with high-risk embolic features, which subsequently underwent near-complete dissolution with rivaroxaban after 3 months.